PSUR

PSUR - Periodic Safety Update Reports

Our experienced and expert clinical research team can support you further in the writing of periodic safety update reports (PSUR). In the PSUR an in-depth risk-benefit analysis of the investigational medicinal product (carried out at the international level) is presented. The aim of this analysis is to document the safety of an active substance for the attention of the competent authorities amongst others.

Naturally, we also provide medical translation services for the translation of PSUR into different languages.

We place great emphasis on customer-oriented service and working to international standards, not only in the development of PSUR, but for all projects that we manage for companies and institutions in the pharmaceutical, biotechnology, medical device, diagnostic, medical technology, cosmetic, nutrition, luxury foodstuffs and consumer goods industries.  Our highly-qualified, multidisciplinary team of personnel with many years of experience is well matched to the task of writing PSUR. Our services in this area are being built up steadily at the international level and this continuous expansion is underpinned by our exacting quality assurance measures. Thus, for the development of PSUR, we additionally provide a sound basis for close cooperation and open lines of communication with our customers.

PSUR and Dr. Oestreich + Partner GmbH Further Services

In addition to the writing of periodic safety update reports (PSUR), Dr. Oestreich + Partner provides services in the development of other types of medical documents. These include study protocols, case report forms (CRFs), electronic case report forms (eCRFs), electronic data bases for the archiving of images from diagnostic procedures, patient information and informed consent forms (ICF), applications to competent authorities and ethics committees for clinical trial authorisation, the reporting of serious adverse events (SAE), the writing of expert reports, clinical study reports, and information on investigational medicinal product (IMP) and medical device characteristics, plus documentation for doctors and public relations material.  The translation of medical texts and PSUR is also part of the wide range of services provided by Dr. Oestreich + Partner GmbH.

Furthermore, in the marketing area, we offer pharmacovigilance (product safety) services. In cooperation with our long-standing partners we are also able to provide, in addition to PSUR, expert clinical trial supply services, to include labelling, packaging, storage and shipment of medicinal products and medical devices.

  Learn more about our services in the section “Development of Medical Documentation and PSURs” - Click here!  


EMA Pharmacovigilance
Health care studies
Observational studies
EMA Pharmacovigilance
Medical Biometrics
Approval of Medical Devices
Pharmacovigilance
Clinical Investigators
Clinical Trials
GCP Legislation
GCP - Good Clinical Practice
ICH GCP E6
GCP Guidelines
GCP Compliance
BfArM GCP
Clinical Research Organisation
Contract Research Organisation
PSUR
PSURs
Pharmacoeconomics, Health
Pharmacoeconomic studies
Pharmacoeconomics
Patient Monitoring
Monitoring Clinical Trials
Clinical Monitor
Marketing Authorisation
Medicinal Product Approval
Drug safety
Data management plan
Clinical development
Monitoring investigators
Non-interventional studies (NIS)
Patient recruitment
Phase IV studies
Investigator audit
Investigator qualification
Investigator selection

EMA Pharmacovigilance · Health care studies · Observational studies · EMA Pharmacovigilance · Medical Biometrics · Approval of Medical Devices · Pharmacovigilance · Clinical Investigators · Clinical Trials · GCP Legislation · GCP - Good Clinical Practice · ICH GCP E6 · GCP Guidelines · GCP Compliance · BfArM GCP · Clinical Research Organisation · Contract Research Organisation · PSUR · PSURs · Pharmacoeconomics, Health · Pharmacoeconomic studies · Pharmacoeconomics · Patient Monitoring · Monitoring Clinical Trials · Clinical Monitor · Marketing Authorisation · Medicinal Product Approval · Drug safety · Data management plan · Clinical development · Monitoring investigators · Non-interventional studies (NIS) · Patient recruitment · Phase IV studies · Investigator audit · Investigator qualification · Investigator selection